神经退行性蛋白质病变中的医疗复杂性:叙述性审查
Seyed-Mohammad Fereshtehnejad1,2,3, Johan Lökk3
1Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T 2S8, Canada.
像阿尔茨海默氏症和帕金森症这样的神经退行性蛋白质病变存在复杂的医疗保健挑战. 早期检测,创新的护理和预防策略对于管理这些进展性疾病和减少患者和护理人员负担至关重要.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 神经退行性蛋白质病变,包括阿尔茨海默病 (AD),帕金森病 (PD) 和患有莱维体痴呆症 (DLB) 的神经退行性蛋白质病,由于人口老龄化,在全球范围内正在上升.
- 这些疾病表现出复杂的病因,重叠的病理和渐进的衰退,给患者,护理人员和医疗保健系统带来了巨大的负担.
研究的目的:
- 综合当前关于与主要神经退行性蛋白质病变相关的医疗复杂性的证据.
- 确定知识差距,并为这些疾病提供未来的护理模式,政策和研究方向.
主要方法:
- 使用PubMed/MEDLINE对相关的MeSH术语和关键词进行了全面的文献搜索.
- 包括专注于与衰老相关的神经退行性蛋白质病变的临床,病理生理学,经济或护理相关复杂性的研究.
主要成果:
- 确定的关键主题包括多因素病因,生物标志物的长期前性阶段,缺乏疾病修饰疗法和渐进性护理需求.
- 还强调了护理人员的高负担,不断上升的医疗保健成本,以及多学科护理模式的重要作用.
结论:
- 复杂性和成本需要以预防为重点的策略,创新的护理,早期干预和为患者和护理人员提供综合支持的政策.
- 研究有效的疾病修饰疗法和改善早期检测对于减轻这些疾病的长期影响至关重要.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
相关概念视频
Parkinson's Disease: Overview
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Dementia
The progression of dementia is generally gradual....
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
